Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients

Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy†

(2013) F. -W. Kreth et al.   ANNALS OF ONCOLOGY

Glioblastoma with Oligodendroglioma Component (GBM-O): Molecular Genetic and Clinical Characteristics

(2013) Christina L. Appin et al.   BRAIN PATHOLOGY

The next step in brain tumor classification: “Let us now praise famous men”… or molecules?

(2012) David N. Louis   ACTA NEUROPATHOLOGICA

Gliosis Versus Glioma?

(2012) Marie Rivera-Zengotita et al.   ADVANCES IN ANATOMIC PATHOLOGY

KIAA1549-BRAFFusions and IDH Mutations Can Coexist in Diffuse Gliomas of Adults

(2012) Manuela Badiali et al.   BRAIN PATHOLOGY

Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma

(2012) Ghazaleh Tabatabai et al.   Current Neurology and Neuroscience Reports

Molecular predictors of outcome in low-grade glioma

(2012) Markus Weiler et al.   CURRENT OPINION IN NEUROLOGY

Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951

(2012) Lale Erdem-Eraslan et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice

(2012) M. Weller et al.   NEURO-ONCOLOGY

Optical needle endoscope for safe and precise stereotactically guided biopsy sampling in neurosurgery

(2012) Werner Göbel et al.   OPTICS EXPRESS

A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts

(2011) Deborah S. Malley et al.   ACTA NEUROPATHOLOGICA

IDH1mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival

(2011) Niklas Thon et al.   CANCER

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas

(2011) Jörg Felsberg et al.   INTERNATIONAL JOURNAL OF CANCER

α-Internexin in the Diagnosis of Oligodendroglial Tumors and Association With 1p/19q Status

(2011) Sabina Eigenbrod et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas

(2011) M. Kunz et al.   NEURO-ONCOLOGY

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide

(2010) N. Thon et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Monoclonal antibody specific for IDH1 R132H mutation

(2009) David Capper et al.   ACTA NEUROPATHOLOGICA

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma

(2009) Andrey Korshunov et al.   ACTA NEUROPATHOLOGICA

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors

(2009) David Capper et al.   BRAIN PATHOLOGY

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel Molecular Stereotactic Biopsy Procedures Reveal Intratumoral Homogeneity of Loss of Heterozygosity of 1p/19q and TP53 Mutations in World Health Organization Grade II Gliomas

(2009) Niklas Thon et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE